Thangathurai Kartheeswaran

Thangathurai Kartheeswaran


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
HMHirotaka Miyashita
Hirotaka Miyashita
RKRazelle Kurzrock
Razelle Kurzrock
NBNicholas J. Bevins
Nicholas J. Bevins
TKThangathurai Kartheeswaran
Thangathurai Kartheeswaran
SLSuzanna Lee
Suzanna Lee
SKShumei Kato
Shumei Kato
Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneity. We interrogated transcriptomics of 15 TPMs (CD137, CD27, CD28, CD80, CD86, CD40, CD40LG, GITR, ICOS, ICOSLG, OX40, OX40LG, GZMB, IFNG, and TBX21) in a pan-cancer cohort (N = 514 patients, 30 types of cancer). TPM expression was analyzed for correlation with histological type, microsatellite instability high (MSI-H), tumor mutational burden (TMB), and programmed death-ligand 1 (PD-L1) expression. Among 514 patients, the most common histological types were colorectal (27%), pancreatic (11%), and breast cancer (10%). No statistically significant association between histological type and TPM expression was seen. In contrast, expression of GZMB (granzyme B, a serine protease stored in activated T and NK cells that induces cancer cell apoptosis) and IFNG (activates cytotoxic T cells) were significantly higher in tumors with MSI-H, TMB ≥ 10 mutations/mb and PD-L1 ≥ 1%. PD-L1 ≥ 1% was also associated with significantly higher CD137, GITR, and ICOS expression. Patients’ tumors were classified into “Hot”, “Mixed”, or “Cold” clusters based on TPM expression using hierarchical clustering. The cold cluster showed a significantly lower proportion of tumors with PD-L1 ≥ 1%. Overall, 502 patients (98%) had individually distinct patterns of TPM expression. Diverse expression patterns of TPMs independent of histological type but correlating with other immunotherapy biomarkers (PD-L1 ≥ 1%, MSI-H and TMB ≥ 10 mutations/mb) were observed. Individualized selection of patients based on TPM immunomic profiles may potentially help with immunotherapy optimization.

24 August 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
JJJessica Jou
Jessica Jou
SKShumei Kato
Shumei Kato
HMHirotaka Miyashita
Hirotaka Miyashita
TKThangathurai Kartheeswaran
Thangathurai Kartheeswaran
SPSarabjot Pabla
Sarabjot Pabla
RKRazelle Kurzrock
Razelle Kurzrock
Our objective was to characterize cancer-immunity marker expression in gynecologic cancers and compare immune landscapes between gynecologic tumor subtypes and with nongynecologic solid tumors. RNA expression levels of 51 cancer-immunity markers were analyzed in patients with gynecologic cancers versus nongynecologic cancers, and normalized to a reference population of 735 control cancers, ranked from 0 to 100, and categorized as low (0–24), moderate (25–74), or high (75–100) percentile rank. Of the 72 patients studied, 43 (60%) had ovarian, 24 (33%) uterine, and 5 (7%) cervical cancer. No two immune profiles were identical according to expression rank (0–100) or rank level (low, moderate, or high). Patients with cervical cancer had significantly higher expression level ranks of immune activating, proinflammatory, tumor-infiltrating lymphocyte markers, and checkpoints than patients with uterine or ovarian cancer (P < 0.001 for all comparisons). However, there were no significant differences in immune marker expression between uterine and ovarian cancers. Tumors with PD-L1 tumor proportional score (TPS) ≥1% versus 0% had significantly higher expression levels of proinflammatory markers (58 vs. 49%, P = 0.0004). Compared to patients with nongynecologic cancers, more patients with gynecologic cancers express high levels of IDO-1 (44 vs. 13%, P < 0.001), LAG3 (35 vs. 21%, P = 0.008), and IL10 (31 vs. 15%, P = 0.002.) Patients with gynecologic cancers have complex and heterogeneous immune landscapes that are distinct from patient to patient and from other solid tumors. High levels of IDO1 and LAG3 suggest that clinical trials with IDO1 inhibitors or LAG3 inhibitors, respectively, may be warranted in gynecologic cancers.

7 September 2020 in Multimedia Tools and Applications
Verified
Journal Article
Closed access
PDF file
PKParameswaran Kovelan
Parameswaran Kovelan
TKThangathurai Kartheeswaran
Thangathurai Kartheeswaran
NTNadarajah Thisenthira
Nadarajah Thisenthira

16 February 2023 in Research Square
Verified
Preprint
Open access
PDF file
JJJessica Jou
Jessica Jou
SKShumei Kato
Shumei Kato
HMHirotaka Miyashita
Hirotaka Miyashita
TKThangathurai Kartheeswaran
Thangathurai Kartheeswaran
SPSarabjot Pabla
Sarabjot Pabla
RKRazelle Kurzrock
Razelle Kurzrock
Background: Our objective was to characterize cancer immunity marker expression in gynecologic cancers and compare immune landscapes between gynecologic tumor subtypes and with non-gynecologic solid tumors. Methods: RNA expression levels of 51 cancer-immunity markers were analyzed in patients with gynecologic cancers vs. non-gynecologic cancers, and normalized to a reference population of 735 control cancers, ranked from 0-100, and categorized as low (0-24), moderate (25-74), or high (75-100) percentile rank. Results: Of the 72 patients studied, 43 (60%) had ovarian, 24 (33%) uterine, and 5 (7%) cervical cancer. No two immune profiles were identical according to expression rank (0-100) or rank level (low, moderate, or high). Patients with cervical cancer had significantly higher expression level ranks of immune activating, pro-inflammatory, tumor infiltrating lymphocyte markers and checkpoints than patients with uterine or ovarian cancer (p1% versus 0% had significantly higher expression levels of pro-inflammatory markers (58 vs. 49%, p=0.0004). Compared to patients with non-gynecologic cancers, more patients with gynecologic cancers express high levels of IDO-1 (44 vs. 13%, p<0.001), LAG3 (35 vs. 21%, p=0.008) and IL10 (31 vs. 15%, p=0.002.) Conclusions: Patients with gynecologic cancers have complex and heterogeneous immune landscapes that are distinct from patient to patient and from other solid tumors. High levels of IDO1 and LAG3 suggest that clinical trials with IDO1 inhibitors or LAG3 inhibitors, respectively, may be warranted in gynecologic cancers.

1 December 2015
Verified
Conference Paper
Closed access
TKThangathurai Kartheeswaran
Thangathurai Kartheeswaran
VSV. Senthooran
V. Senthooran
TPT D D L Pemadasa
T D D L Pemadasa
Today's Information Technology grows rapidly with new technologies and need more security for the data transmission over the internet. Steganography is one of the solutions to ensure the data secure over the internet. An audio steganography is a method to transfer concealed information by changing the cover audio file without degrading the quality of the original file. The cover medium before steganography and stego medium after steganography should have the same characteristics of a good steganographic system. The Agent technology involves distributing the services with flexible manner. As most of the applications are created as services in present computing scenario and data security also can be served as a service. Agent-based steganography will improve the efficiency of the secure steganographic system and it will be more convenient in terms of flexibility and availability. In this research paper, we present a trusted communication platform for multi-agents that are able to hide the confidential message in the cover audio stream according to the user request and retrieve the hidden information from the stego audio file. This system provides high availability and flexibility in this context and a more feasible way to trust the message transmission. This work is currently being done and designing part of this work has been done successfully with satisfied results.

6 February 2024 in Multimedia Tools and Applications
Verified
Journal Article
Closed access
PDF file
RGRomiyal George
Romiyal George
LNLojenaa Navanesan
Lojenaa Navanesan
TKThangathurai Kartheeswaran
Thangathurai Kartheeswaran